Michael Vodicka is the president and founder of the Vodicka Group Inc., a registered investment advisor (RIA) that specializes in providing customized investment solutions to individual and institutional investors. Before becoming a small business owner and entrepreneur, he developed fixed-income investment strategies for a multi-billion dollar brokerage firm and spent five years as an equity portfolio manager for a private investment research company. Mike graduated from the University of Kansas with a degree in business communications and is a licensed investment advisor (Series 65). He loves sharing his passion for the market and investing with clients and readers alike.

Analyst Articles

Warren Buffett made billions with his trusted buy-and-hold model. But in the past 12 years, with investors battling abnormal amounts of volatility and getting burned in the dot-com bubble of 2000, the 9/11 attacks, the housing crash of 2006, the financial crisis of 2008 and the U.S. credit rating downgrade in 2011, many investors have chosen to abandon the buy-and-hold strategy to stay more nimble. Take a look at the… Read More

Warren Buffett made billions with his trusted buy-and-hold model. But in the past 12 years, with investors battling abnormal amounts of volatility and getting burned in the dot-com bubble of 2000, the 9/11 attacks, the housing crash of 2006, the financial crisis of 2008 and the U.S. credit rating downgrade in 2011, many investors have chosen to abandon the buy-and-hold strategy to stay more nimble. Take a look at the chart below for a closer look at how volatility has rocked the market ever since the dot-com implosion of early 2000 — it’s truly remarkable: S&P 500 Monthly Chart 1950-2012 This volatility trend has driven the growing popularity of technical indicators designed to help investors decide when to buy and sell stocks. Unlike fundamental analysis, which uses earnings, dividends and valuation, technical analysis… Read More

Income investors can find attractive high-yields in the pharmaceutical sector right now. Many major drug makers, including familiar names like Merck (NYSE: MRK), Johnson & Johnson (NYSE: JNJ) and Bristol Myers Squibb (NYSE: BMY), are yielding close to 4% or better. But with so many stocks in this segment, deciding… Read More